Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline.
Link to Article:
https://www.panthera-bio.com/news/
At the Rutherford Cancer Centre North East, the first multisite oncology trial conducted by the independent sector in the UK has begun treating its first patient. This collaboration between Rutherford Health and Panthera will increase the UK’s capacity to conduct oncology research and give cancer patients more treatment alternatives. More than ten other oncology trials are currently in the works for the alliance.
While the UK has some of the world’s best cancer hospitals, the capacity to conduct oncology studies in the UK has been hampered by Covid-19, which has resulted in a significant treatment and diagnostics backlog.
More than 75,000 cancer studies are currently active around the world, with the number continually increasing.
Two of the four Panthera@theRutherford Cancer Centres throughout the UK are participating in phase II open label, non-randomised prostate cancer trial that is looking into a potential treatment for an advanced form of prostate cancer known as metastatic castration-resistant cancer (mCRPC). About 20% of patients with mCRPC are thought to have the biomarker that qualifies them for the new medication being tested.
The first individual in the UK to receive this new medicine was a 71-year-old patient from Middlesbrough. He will get therapy at the Rutherford Cancer Centre North East in Bedlington for at least a year.